BioSpace News Archive

John Theurer Cancer Center at Hackensack University Medical Center, New Jersey’s top ranked cancer center, according to U.S. News & World Report, announced that it has treated the first patient in the country with DSP-0390, an investigational new drug for relapsed glioblastoma and other anaplastic gliomas.

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2021 results for the period ended December 31, 2021.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that the Board of Directors and Mark Mallon, Chief Executive Officer, have agreed that Mr. Mallon will step down as CEO and member of the Board, effective immediately.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced two key appointments to its new management structure.

Vyant Bio, Inc., is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

IDEX CORPORATION announced that it has scheduled the broadcast of the company’s first quarter earnings conference call over the Internet on Wednesday, April 27, 2022 at 9:30 a.m. CT.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.

Everest Medicines announced its financial results for full year ended December 31, 2021, along with a corporate progress update.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the company and presented preliminary financial results for the year ended December 2021.

Innovent Biologics, Inc. announced the first patient dosing for its proprietary recombinant bispecific antibody targeting Claudin18.2 and CD3 in a Phase I clinical trial for the treatment of advanced malignancies.